The Latest Breaking News from Moderna

Oxford University and Moderna launch trials of vaccine that could prevent cancer

The jab targets patients with Lynch syndrome, who are at high risk of colorectal and ovarian cancer

The Independent UK · Jun 8

Moderna Stock: Is MRNA Outperforming the Health Care Sector?

Although Moderna has outperformed the broader health care sector over the last 12 months, analysts maintain a cautious stance on the stock’s future outlook.

Barchart · Jun 4

Serum Institute of India to manufacture Oxford Ebola vaccine backed by $8.6 million CEPI funding

Serum Institute of India will produce clinical trial doses of a new Ebola vaccine from Oxford University. This initiative is backed by fresh funding to combat a spreading outbreak in Africa. The vaccine uses technology similar to the Oxford-AstraZeneca Covid-19 vaccine. This partnership aims to accelerate development and ensure access…

The Economic Times · Jun 2

Is There A Cure For Hantavirus Infection? 'Breathed In' Virus Kills 38% Of Patients, Scientists Race For Vaccine

A deadly cruise ship outbreak of the Andes strain has revived global interest in a long‑delayed hantavirus cure, as scientists warn that early hospital care can make the difference between survival and a 38% fatality risk.

International Business Times UK · May 11

Moderna Stock Is Surging on Hantavirus Threats. Its Chart Offers a Harsh Dose of Reality.

A localized outbreak, even a fatal one, is unlikely to spark the multibillion-dollar revenue catalyst that Moderna needs.

Barchart · May 11

Is Wall Street Bullish or Bearish on Moderna Stock?

Moderna has notably outperformed the broader market over the past year, yet Wall Street analysts maintain a cautious outlook about the stock’s prospects.

Barchart · May 6

Major trial for human bird flu vaccine launches

Around 4,000 people will be recruited for the study, the majority of which will be in the UK.

Evening Standard · Apr 21

Bird flu vaccine trial begins to fight ‘real possibility’ of virus threat for humans

The vaccine will utilise mRNA technology similar to that employed in Covid-19 jabs

The Independent UK · Apr 21

Moderna's Quarterly Earnings Preview: What You Need to Know

Moderna is expected to announce its fiscal first-quarter earnings next month, and analysts project a high single-digit decline in losses.

Barchart · Apr 20

What to know about OpenAI's new model for life sciences research GPT-Rosalind

The GPT-Rosalind model is designed to accelerate biological research and drug discovery.

Euronews · Apr 17